MatriPlax
Phase 1Small molecule
MatriPlax is one of 21 small molecule programs targeting Acute Respiratory Distress Syndrome. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Acute Respiratory Distress Syndrome
#DrugCompanyPhaseTrials
1Revia
TevaApproved
Bayer Aspirin
BayerApproved
Decadron
AAspen Global Incorporated
Approved
Esbriet
LLegacy Health System
Approved
Foradil
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Duragesic
CCephalon
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Supportive Care
BeiGenePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MatriPlax. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBioSpring Medical Co., Ltd